FDA Inspection 1273119 — Cyrus Desouza
The FDA completed an inspection of Cyrus Desouza on June 5, 2025 in Omaha, NE. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- June 5, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Omaha, NE (United States)
Additional Details
Clinical Investigator (CI)